CTOS BOARD OF DIRECTORS 2000–2001

Jaap Verweij, MD President
Lee Helman, MD Vice President
Mark Gebhardt, MD Secretary
Robert S. Benjamin, MD Treasurer
Brian O’Sullivan, MD Past President

J. Sybil Biermann, MD (1998–2001)
Vivien Bramwell-Wesley, MD (1998–2001)
Ian Judson, MD (1998–2001)
Claude Turc-Carel, MD (1998–2001)
Frits Van Coevorden, MD (1998–2001)
Franco Gherlinzoni, MD (1999–2002)
Michael Simon, MD (1999–2002)
Scott Nelson, MD (1999–2002)
Martine van Glabbeke, MD (1999–2002)
Andrew Huvos, MD (2000–2003)
CTOS Meeting Program

Thursday, November 1, 2001
1:00–5:00 p.m.    Registration, Set Up Posters
6:00–7:00 p.m.    Welcome Reception

Friday, November 2, 2001
7:00 a.m.    Registration, Breakfast for meeting attendees
7:00 a.m.    Executive Committee Meeting
8:00 a.m.    Welcome, Opening Announcements: Jaap Verweij, CTOS President

8:15 a.m. PEDIATRIC SARCOMAS: Chairmen: Lee Helman (USA) & Herbert Jurgens (Germany)
8:15 a.m.    Herbert Jurgens: Pediatric sarcoma: state of the art
8:30 a.m.    Tim Triche: From gene activation to signal transduction treatment
8:45 a.m.    Lenny Wexler: Irinotecan in refractory RMS
9:00 a.m.    Peter Anderson: Inhalation GMCSF for treatment of pulmonary metastases
9:15 a.m.    Abstract number 40 Her-2/NEU staining in osteosarcoma: association with increased risk of metastasis—Holly Zhou, Rob Goldsby, R. Lor Randall, Lynn Smith, Cheryl M. Coffin Departments of Pathology, Pediatrics, Orthopedics, and Radiation Oncology, University of Utah
9:30 a.m.    Summary and Panel Discussion: Where do we go from here? Lee Helman

10.00 a.m.    Coffee Break, Poster Viewing

10:15 a.m. BONE TUMORS: Chairmen: Peter Choong (Australia) & Thor Alvegard (Sweden)
10:15 a.m.    Linda Granowetter: US Ewing’s sarcoma randomized study of higher dose therapy
10:30 a.m.    Kristy Weber: Implications and management of local relapse in Ewing’s sarcoma
10:45 a.m.    Peter Choong: The role of functional nuclear scanning in sarcoma management
11:00 a.m.    Sigbjørn Smeland: An overview of treatments results in osteosarcoma: is there a need for a global collaboration?
11:15 a.m.    Abstract number 87 Reconstruction of the pelvis following resection of tumors about the acetabulum—R. L. Satcher, Jr., R. J. O’Donnell, J. O. Johnston, University of California, San Francisco
11:30 a.m.    Abstract number 22 Curative treatment and effective palliation with hemipelvectomy—A useful operation: modern concepts based on 20 years of experience—James C Wittig, Jacob Bickels, Felasfa Wodajo, Kristen L. Kellar-Graney, Yehuda Kollender, Isaac Meller, Martin M Malawer Division of Orthopedic Oncology, Washington Cancer Institute and National Unit of Orthopedic Oncology, Tel-Aviv Sourasky Medical Center
11:45 a.m.    Abstract number 16 (Young Investigator Award Winner) Bugged out? Infection and endoprosthetic replacements—Lee M Jeys, Raj Suneja, Vishnu Prasad, Robert Grimer, Simon R Carter, Roger Tillman Royal Orthopaedic Hospital Oncology Service, Royal Orthopaedic Hospital
12:00 p.m    Summary and Panel Discussion: Where do we go from here? Thor Alvegard

12:15 p.m.    Buffet Lunch, Poster Viewing
12:15 p.m    Board of Directors Meeting

1:15 p.m.     Jaap Verweij, CTOS President: Presentations of Two Young Investigator Awards (Lee M Jeys, Jonathan C Trent)
1:30 p.m. **SOFT TISSUE SARCOMAS:** Chairmen: Jean-Yves Blay (France) & Brian O’Sullivan (Canada)

1:30 p.m. Pancras Hogendoorn: Grading of soft tissue tumours
1:45 p.m. Peter Pisters: Preoperative chemoradiotherapy for locally advanced soft tissue sarcomas
2:00 p.m. Brian O’Sullivan: The advantage of new radiotherapy technologies in the management of soft tissue sarcoma
2:15 p.m. Controversy session: polychemotherapy vs. monochemotherapy in advanced sarcomas:
2:15 p.m. pro: Bob Benjamin
2:30 p.m. contra: Jaap Verweij
2:45 p.m. Discussion
3:00 p.m. **Abstract number 56** Margin width has prognostic significance for extremity and truncal sarcoma—Mark D.McKee, Dong Feng Liu, Deborah Driscoll, John J. Brooks, John F. Gibbs, William G. Kraybill Roswell Park Cancer Institute
3:15 p.m. Summary & Panel Discussion: Where do we go from here? Jean Yves Blay

3:45 p.m. Coffee Break, Poster Viewing

4:00 p.m. **BASIC SCIENCE/BIOLOGY:** Jonathan Fletcher (USA) & Junya Toguchida (Japan)

4:00 p.m. Marc Ladanyi: Alveolar soft part sarcoma oncogene
4:20 p.m. Charlie Roberts: SNF5/INI1 haploinsufficiency predisposes to rhabdoid tumors in mice
4:40 p.m. Paul Meltzer: Clinical and biological applications of sarcoma gene expression profiling
5:00 p.m. **Abstract number 106** Gene-expression profiles in chondrosarcomas and chordomas—Thomas F. DeLaney, Brian Seed, Ramnik Xavier, Andrew L. Rosenberg, G. Petur Nielsen, Francis J. Hornicek, Norbert J. Liebsch, John E. Munzenrider, Herman D. Suit, Massachusetts General Hospital
5:15 p.m. Summary and Panel discussion: Jonathan Fletcher & Junya Toguchida

6:00–6.30 p.m. Members’ Business Meeting

7:15 p.m. CTOS Reception and Dinner Banquet

---

**Saturday, November 3, 2001**

7:00 a.m. Registration, Breakfast for meeting attendees
8:00 a.m. **NINA AXELRAD KEYNOTE LECTURE** (Supported by the Nina Axelrod Sarcoma Fund):
Allan van Oosterom (Leuven, Belgium): Systemic treatment of advanced soft tissue sarcomas is not uniform any longer; Glivec as a paradigm.

9:00 a.m. **IMATINIB MESYLATE (DEVELOPED AS STI-571):** George Demitri (USA) & Jaap Verweij (Netherlands)

9:00 p.m. Brian Rubin: Biology of GISTs
9:15 p.m. George Demitri: The USA experience
9:30 p.m. Jaap Verweij: The EORTC phase 2 study
9:45 p.m. **Abstract number 131** (Young Investigator Award Winner) Inhibition of PDGF receptor tyrosine kinase in human soft-tissue sarcoma—Jonathan C. Trent, Jonathan Hannay, Lan Li, Shreyaskumar Patel, Robert S. Benjamin, Raphael E. Pollock, Di-Hua Yu The University of Texas, M. D. Anderson Cancer Center
10:00 p.m. Panel Discussion: Where do we go from here? George Demitri & Jaap Verweij
10:15 a.m. Coffee Break, Poster Viewing

10:30 a.m. **Workshop: Genetics of Sarcoma:** Jonathan Fletcher (USA) & Lee Helman (USA)

- **10:30 a.m.** Paola Dal Cin: Novel cytogenetic mechanisms in mesenchymal tumors
- **10:50 a.m.** Marc Ladanyi: Specificity and clinical correlations for SYT-SSX
- **11:10 a.m.** **Abstract number 130** Expression profiling of osteosarcoma biopsies and metastases with CDNA microarrays—Luca Sangiorgi, Giuliana Alessandra Gobbi, Enrico Lucarelli, Francesca Scrimieri, Piero Picci, Paul Meltzer, Lab. Oncology Research, Rizzoli Orthopedic Institute, and Section of Molecular Genetics, Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health
- **11:25 a.m.** Summary and Panel Discussion: Where do we go from here? Jonathan Fletcher & Lee Helman

11:45 a.m. Buffet Lunch, Poster Viewing

12:45 p.m. **COOPERATIVE GROUP RESEARCH:** Jaap Verweij (The Netherlands) & Karen Antman (USA)

1:45 p.m. **Mini Symposium: STAGING, RESPONSE ASSESSMENT & FOLLOW-UP:** Peter Hohenberger (Germany) & Ian Judson (UK)

- **1:45 p.m.** Jan Bloem: Staging and dynamic contrast enhanced MRI for response assessment
- **2:00 p.m.** Peter Hohenberger: 31P magnetic resonance spectroscopy (31P-MRS) for non-invasive assessment of pathohistologic tumor response of soft tissue sarcoma
- **2:15 p.m.** A. Kevin Raymond: Pathohistological response assessment following systemic chemotherapy for sarcomas
- **2:30 p.m.** Summary and Panel Discussion: Where do we go from here? Ian Judson

2:45 p.m. **CASE DISCUSSIONS: ANGIOSARCOMAS** Paolo Casali (Italy)

- **Medical Oncology:** Paolo Casali
- **Pathology:** John Brooks
- **Surgery:** Sylvie Bonvalot
- **Radiotherapy:** Kirsten Sundby Hall

3:45 p.m. Adjournment
Submit your manuscripts at http://www.hindawi.com